title: Early steroid withdrawal in pediatric renal transplant on newer immunosuppressive drugs.
abstract: Steroids have been a cornerstone in renal transplant immunosuppression. New immunosuppressive drugs have led to protocols using early steroid withdrawal or complete avoidance. A prospective protocol in 23 pediatric renal transplant (ages 2-14 yr) who received decreasing steroid doses stopping at day 7 post-Tx, FK, and MMF were compared with a CsA, AZT, historically matched steroid-based control group. Basiliximab was used in two doses. Anthropometric, biochemical variables, AR rates, and CMV infection were evaluated and compared using Student's t-test and regression analysis. A better growth pattern was seen in steroid withdrawal group. GFR rate and serum glucose were similar in both groups. Total serum cholesterol levels were significantly lower in steroid withdrawal group. The incidence of AR at 12 months was 4.3% in steroid withdrawal group vs. 8.6% in steroid-based group (p = ns). No difference in CMV infection was observed. Hemoglobin levels were low during the first months in both groups; reached normal values after six months. SBP became higher at 12 months in steroid-based group. Patient and graft survival was 98% in both groups at one-yr post-transplant. Early steroid withdrawal was efficacious, safe, and did not increase risk of rejection, preserving optimal growth, renal function, and reducing cardiovascular risk factors.
authors.affiliation: Pediatrics, Calvo Mackenna Hospital, Santiago, Chile. angeladelucchi@vtr.net
authors.forename: Angela
authors.initials: A
authors.lastname: Delucchi
authors.forename: Marcela
authors.initials: M
authors.lastname: Valenzuela
authors.forename: Mario
authors.initials: M
authors.lastname: Ferrario
authors.forename: Ana Maria
authors.initials: AM
authors.lastname: Lillo
authors.forename: J Luis
authors.initials: JL
authors.lastname: Guerrero
authors.forename: Eugenio
authors.initials: E
authors.lastname: Rodriguez
authors.forename: Francisco
authors.initials: F
authors.lastname: Cano
authors.forename: Gabriel
authors.initials: G
authors.lastname: Cavada
authors.forename: Jorge
authors.initials: J
authors.lastname: Godoy
authors.forename: Jorge
authors.initials: J
authors.lastname: Rodriguez
authors.forename: C Gloria
authors.initials: CG
authors.lastname: Gonzalez
authors.forename: Erwin
authors.initials: E
authors.lastname: Buckel
authors.forename: Luis
authors.initials: L
authors.lastname: Contreras
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000077552:Basiliximab; D002648:Child; D002675:Child, Preschool; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology*; D011446:Prospective Studies; D011627:Puberty; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab